{"id":"https://openalex.org/W2285511451","doi":null,"title":"A phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies","display_name":"A phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies","publication_year":2007,"publication_date":"2007-11-01","ids":{"openalex":"https://openalex.org/W2285511451","mag":"2285511451"},"language":"en","primary_location":{"id":"mag:2285511451","doi":null,"is_oa":false,"landing_page_url":"http://mct.aacrjournals.org/content/6/11_Supplement/A152","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":null},"volume":null,"type":"article","indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5003826371","display_name":"Ravi Salgia","orcid":"https://orcid.org/0000-0001-9643-7626","observed_orcids":["https://orcid.org/0000-0001-9643-7626"]},"institutions":[{"id":"https://openalex.org/I152988861","display_name":"Exelixis (United States)","ror":"https://ror.org/01e3jga91","country_code":"US","type":"company","lineage":["https://openalex.org/I152988861"]},{"id":"https://openalex.org/I4210087865","display_name":"University of Chicago Medical Center","ror":"https://ror.org/0076kfe04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ravi Salgia","raw_affiliation_strings":["The University of Chicago Medical Center, Chicago, IL, MD Anderson Cancer Center, Houston, TX, Exelixis, Inc., South San Francisco, CA"],"raw_orcid":"https://orcid.org/0000-0001-9643-7626","affiliations":[{"raw_affiliation_string":"The University of Chicago Medical Center, Chicago, IL, MD Anderson Cancer Center, Houston, TX, Exelixis, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I152988861","https://openalex.org/I4210087865"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026095888","display_name":"David S. Hong","orcid":"https://orcid.org/0000-0001-8721-1609","observed_orcids":["https://orcid.org/0000-0001-8721-1609"]},"institutions":[{"id":"https://openalex.org/I152988861","display_name":"Exelixis (United States)","ror":"https://ror.org/01e3jga91","country_code":"US","type":"company","lineage":["https://openalex.org/I152988861"]},{"id":"https://openalex.org/I4210087865","display_name":"University of Chicago Medical Center","ror":"https://ror.org/0076kfe04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David S. Hong","raw_affiliation_strings":["The University of Chicago Medical Center, Chicago, IL, MD Anderson Cancer Center, Houston, TX, Exelixis, Inc., South San Francisco, CA"],"raw_orcid":"https://orcid.org/0000-0001-8721-1609","affiliations":[{"raw_affiliation_string":"The University of Chicago Medical Center, Chicago, IL, MD Anderson Cancer Center, Houston, TX, Exelixis, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I152988861","https://openalex.org/I4210087865"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022246066","display_name":"Steven A. Sherman","orcid":"https://orcid.org/0000-0002-8608-6575","observed_orcids":["https://orcid.org/0000-0002-8608-6575"]},"institutions":[{"id":"https://openalex.org/I152988861","display_name":"Exelixis (United States)","ror":"https://ror.org/01e3jga91","country_code":"US","type":"company","lineage":["https://openalex.org/I152988861"]},{"id":"https://openalex.org/I4210087865","display_name":"University of Chicago Medical Center","ror":"https://ror.org/0076kfe04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven Sherman","raw_affiliation_strings":["The University of Chicago Medical Center, Chicago, IL, MD Anderson Cancer Center, Houston, TX, Exelixis, Inc., South San Francisco, CA"],"raw_orcid":"https://orcid.org/0000-0002-8608-6575","affiliations":[{"raw_affiliation_string":"The University of Chicago Medical Center, Chicago, IL, MD Anderson Cancer Center, Houston, TX, Exelixis, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I152988861","https://openalex.org/I4210087865"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110317827","display_name":"Chann Ng","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I152988861","display_name":"Exelixis (United States)","ror":"https://ror.org/01e3jga91","country_code":"US","type":"company","lineage":["https://openalex.org/I152988861"]},{"id":"https://openalex.org/I4210087865","display_name":"University of Chicago Medical Center","ror":"https://ror.org/0076kfe04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chann Ng","raw_affiliation_strings":["The University of Chicago Medical Center, Chicago, IL, MD Anderson Cancer Center, Houston, TX, Exelixis, Inc., South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Chicago Medical Center, Chicago, IL, MD Anderson Cancer Center, Houston, TX, Exelixis, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I152988861","https://openalex.org/I4210087865"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037047203","display_name":"John W. Frye","orcid":"https://orcid.org/0000-0002-7869-7181","observed_orcids":["https://orcid.org/0000-0002-7869-7181"]},"institutions":[{"id":"https://openalex.org/I152988861","display_name":"Exelixis (United States)","ror":"https://ror.org/01e3jga91","country_code":"US","type":"company","lineage":["https://openalex.org/I152988861"]},{"id":"https://openalex.org/I4210087865","display_name":"University of Chicago Medical Center","ror":"https://ror.org/0076kfe04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Frye","raw_affiliation_strings":["The University of Chicago Medical Center, Chicago, IL, MD Anderson Cancer Center, Houston, TX, Exelixis, Inc., South San Francisco, CA"],"raw_orcid":"https://orcid.org/0000-0002-7869-7181","affiliations":[{"raw_affiliation_string":"The University of Chicago Medical Center, Chicago, IL, MD Anderson Cancer Center, Houston, TX, Exelixis, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I152988861","https://openalex.org/I4210087865"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071718298","display_name":"Linda A. Janisch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I152988861","display_name":"Exelixis (United States)","ror":"https://ror.org/01e3jga91","country_code":"US","type":"company","lineage":["https://openalex.org/I152988861"]},{"id":"https://openalex.org/I4210087865","display_name":"University of Chicago Medical Center","ror":"https://ror.org/0076kfe04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Linda Janish","raw_affiliation_strings":["The University of Chicago Medical Center, Chicago, IL, MD Anderson Cancer Center, Houston, TX, Exelixis, Inc., South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Chicago Medical Center, Chicago, IL, MD Anderson Cancer Center, Houston, TX, Exelixis, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I152988861","https://openalex.org/I4210087865"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068268371","display_name":"Mark J. Ratain","orcid":"https://orcid.org/0000-0002-0938-4392","observed_orcids":["https://orcid.org/0000-0002-0938-4392"]},"institutions":[{"id":"https://openalex.org/I152988861","display_name":"Exelixis (United States)","ror":"https://ror.org/01e3jga91","country_code":"US","type":"company","lineage":["https://openalex.org/I152988861"]},{"id":"https://openalex.org/I4210087865","display_name":"University of Chicago Medical Center","ror":"https://ror.org/0076kfe04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark J. Ratain","raw_affiliation_strings":["The University of Chicago Medical Center, Chicago, IL, MD Anderson Cancer Center, Houston, TX, Exelixis, Inc., South San Francisco, CA"],"raw_orcid":"https://orcid.org/0000-0002-0938-4392","affiliations":[{"raw_affiliation_string":"The University of Chicago Medical Center, Chicago, IL, MD Anderson Cancer Center, Houston, TX, Exelixis, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I152988861","https://openalex.org/I4210087865"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5053481267","display_name":"Razelle Kurzrock","orcid":"https://orcid.org/0000-0003-4110-1214","observed_orcids":["https://orcid.org/0000-0003-4110-1214"]},"institutions":[{"id":"https://openalex.org/I152988861","display_name":"Exelixis (United States)","ror":"https://ror.org/01e3jga91","country_code":"US","type":"company","lineage":["https://openalex.org/I152988861"]},{"id":"https://openalex.org/I4210087865","display_name":"University of Chicago Medical Center","ror":"https://ror.org/0076kfe04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Razelle Kurzrock","raw_affiliation_strings":["The University of Chicago Medical Center, Chicago, IL, MD Anderson Cancer Center, Houston, TX, Exelixis, Inc., South San Francisco, CA"],"raw_orcid":"https://orcid.org/0000-0003-4110-1214","affiliations":[{"raw_affiliation_string":"The University of Chicago Medical Center, Chicago, IL, MD Anderson Cancer Center, Houston, TX, Exelixis, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I152988861","https://openalex.org/I4210087865"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.6589,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":{"value":0.67259568,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"6","issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.8765000104904175,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.8765000104904175,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T13779","display_name":"Cancer Mechanisms and Therapy","score":0.06790000200271606,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.023600000888109207,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cabozantinib","display_name":"cabozantinib","score":0.9929999709129333},{"id":"https://openalex.org/keywords/met-inhibitors","display_name":"MET inhibitors","score":0.9850000143051147},{"id":"https://openalex.org/keywords/ret-inhibition","display_name":"RET inhibition","score":0.7210000157356262},{"id":"https://openalex.org/keywords/kit","display_name":"KIT","score":0.40299999713897705},{"id":"https://openalex.org/keywords/flt3","display_name":"FLT3","score":0.9629999995231628},{"id":"https://openalex.org/keywords/tie2","display_name":"Tie2","score":0.9210000038146973},{"id":"https://openalex.org/keywords/advanced-cancer","display_name":"advanced cancer","score":0.8100000023841858},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6499999761581421},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7680000066757202},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.7400000095367432},{"id":"https://openalex.org/keywords/elevated-liver-enzymes","display_name":"elevated liver enzymes","score":0.4350000023841858},{"id":"https://openalex.org/keywords/intermittent-dosing","display_name":"intermittent dosing","score":0.6899999976158142},{"id":"https://openalex.org/keywords/oral-anticancer-drugs","display_name":"oral anticancer drugs","score":0.5410000085830688},{"id":"https://openalex.org/keywords/anti-angiogenic-therapy","display_name":"anti-angiogenic therapy","score":0.8349999785423279},{"id":"https://openalex.org/keywords/ret-phosphorylation","display_name":"RET phosphorylation","score":0.5099999904632568}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8250550031661987},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.731560230255127},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6141680479049683},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.5894221067428589},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5699356198310852},{"id":"https://openalex.org/C2780120053","wikidata":"https://www.wikidata.org/wiki/Q3493538","display_name":"Medullary thyroid cancer","level":4,"score":0.5110527276992798},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5019724369049072},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.49416592717170715},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.40734007954597473},{"id":"https://openalex.org/C2779761222","wikidata":"https://www.wikidata.org/wiki/Q826522","display_name":"Thyroid cancer","level":3,"score":0.2333260476589203},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2285511451","doi":null,"is_oa":false,"landing_page_url":"http://mct.aacrjournals.org/content/6/11_Supplement/A152","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2211326371","https://openalex.org/W2246590687","https://openalex.org/W1901650671","https://openalex.org/W1992155294","https://openalex.org/W2278176381","https://openalex.org/W161870460","https://openalex.org/W2278476448","https://openalex.org/W2241761252","https://openalex.org/W2247544749","https://openalex.org/W2246017419"],"abstract_inverted_index":{"A152":[0],"Background:":[2],"XL184":[3,39,56,83,104,324,444,454],"is":[4,148,294,438],"an":[5],"orally":[6,105],"bioavailable":[7],"small":[8],"molecule":[9],"inhibitor":[10],"of":[11,45,87,179,188,262,278,299,323,399,413,419],"MET":[12,74,497],"and":[13,21,26,48,51,131,141,155,212,215,227,234,243,308,374,432,460],"VEGFR2/KDR":[14],"that":[15,256,487],"also":[16],"inhibits":[17,58],"RET,":[18],"KIT,":[19],"FLT3,":[20],"Tie-2":[22],"both":[23],"in":[24,27,29,41,61,90,231,247,258,267,343,371,395,403,429,476,492],"vitro":[25],"vivo":[28],"preclinical":[30,42],"models.":[31],"Significant":[32],"tumor":[33,43,408],"growth":[34,310],"inhibition":[35,86],"was":[36,136],"observed":[37,475],"following":[38],"treatment":[40,382],"models":[44],"human":[46],"breast":[47],"lung":[49],"cancer,":[50,392],"rat":[52],"glioma.":[53],"In":[54],"addition,":[55],"strongly":[57],"cell":[59,68,391],"proliferation":[60],"gastric":[62],"or":[63,72,75,124,168,496],"medullary":[64],"thyroid":[65],"cancer":[66,341],"(MTC)":[67],"lines":[69],"harboring":[70],"activated":[71,76],"overexpressed":[73],"RET.":[77],"Preclinical":[78],"single-dose":[79],"pharmacodynamic":[80],"studies":[81],"with":[82,98,103,125,164,191,367,377,388,416,436,478],"demonstrate":[84],"substantial":[85,427],"RET":[88,424,493],"phosphorylation":[89],"TT":[91],"(MTC":[92],"model)":[93],"xenograft":[94],"tumors.\u2028":[95],"Methods:":[96],"Pts":[97,163],"advanced":[99,192],"malignancies":[100,193],"were":[101],"treated":[102,196],"daily":[106,127,468],"for":[107,383],"5":[108,207,240,414],"days":[109],"followed":[110],"by":[111,160],"a":[112,206,248,303,320,393,397,422,456],"9-day":[113],"non-treatment":[114],"period":[115],"(intermittent":[116],"\u201c5":[117],"&":[118,208,241],"9\u201d":[119],"schedule;":[120],"cohorts":[121],"(C)":[122],"1-9),":[123],"continuous":[126],"dosing":[128,135,469],"(C":[129],"10":[130],"beyond).":[132],"The":[133],"initial":[134],"based":[137],"on":[138,205,325],"body":[139],"weight":[140],"then":[142],"amended":[143],"to":[144,172,202,410,441,452,465,485],"flat":[145],"dosing.":[146],"Response":[147],"assessed":[149],"after":[150],"the":[151,263,268,291,344,347,467],"first":[152],"2":[153,245],"cycles":[154],"every":[156],"8":[157],"wks":[158],"thereafter":[159],"RECIST":[161],"criteria.":[162],"stable":[165],"disease":[166,394],"(SD)":[167],"better":[169],"may":[170,488],"continue":[171],"receive":[173],"treatment.":[174],"Plasma":[175],"markers":[176],"reflecting":[177],"effects":[178],"anti-angiogenic":[180],"therapy":[181],"are":[182],"being":[183],"analyzed.\u2028":[184],"Results:":[185],"A":[186],"total":[187],"38":[189],"pts":[190,265,349,357,415,477],"have":[194,331,351,358,489],"been":[195,474],"across":[197],"11":[198],"dose":[199,259,462],"levels:":[200],"0.08":[201],"11.52":[203,238],"mg/kg":[204,239],"9":[209,356],"schedule":[210],"(C1-9),":[211],"175":[213],"(C10)":[214],"265":[216,252],"mg":[217,253],"(C11)":[218],"PO":[219,254],"QD.":[220],"DLTs":[221],"include":[222],"grade":[223,228,244,281],"3":[224,229],"palmar/plantar":[225],"erythema,":[226],"elevations":[230],"AST,":[232],"ALT":[233],"lipase,":[235],"occurring":[236],"at":[237,251,449],"9,":[242],"mucositis":[246],"pt":[249,366,376,387,435],"dosed":[250],"QD":[255,461],"resulted":[257],"reduction.":[260],"Twenty-three":[261],"33":[264],"included":[266],"most":[269],"recent":[270],"data":[271],"transfer/analysis":[272],"had":[273,332,352,359,421,426],"no":[274],"reported":[275],"XL184-related":[276],"toxicities":[277],"greater":[279],"than":[280],"1.":[282],"Preliminary":[283],"PK":[284],"analysis":[285,298],"(0.08-11.52":[286],"mg/kg)":[287],"suggests":[288],"linear":[289],"PK;":[290],"terminal":[292,458],"half-life":[293,459],"58-136":[295],"hrs.":[296],"Pharmacodynamic":[297],"plasma":[300,430],"samples":[301],"showed":[302],"trend":[304],"towards":[305],"increased":[306],"VEGF-A":[307],"placenta":[309],"factor":[311],"as":[312,314],"well":[313,447],"slightly":[315],"reduced":[316],"sVEGFR2":[317],"levels,":[318],"demonstrating":[319],"pharmacological":[321],"effect":[322],"VEGF":[326],"pathway":[327],"biomarkers.":[328],"Three":[329],"patients":[330],"partial":[333],"responses":[334],"(2":[335],"confirmed,":[336],"MTC;":[337],"1":[338,365,375,434],"unconfirmed,":[339],"neuroendocrine":[340],"originating":[342],"thyroid).":[345],"Of":[346],"14":[348],"who":[350],"SD":[353,360],"\u22653":[354],"months,":[355],"\u2265":[361],"6":[362],"months":[363],"including":[364,481],"carcinoid":[368],"(20%":[369],"decrease":[370],"liver":[372],"metastases)":[373],"cutaneous":[378],"T-cell":[379],"lymphoma":[380],"(on":[381],">18":[384],"mos).":[385],"One":[386],"papillary":[389],"renal":[390],"which":[396],"subset":[398],"cases":[400],"harbor":[401],"mutations":[402],"MET,":[404],"has":[405,455,473],"demonstrated":[406],"15%":[407],"reduction":[409],"date.":[411,453],"Four":[412],"MTC":[417,437],"(two":[418],"whom":[420],"documented":[423],"mutation)":[425],"reductions":[428],"calcitonin":[431],"CEA;":[433],"too":[439],"early":[440],"evaluate.\u2028":[442],"Conclusions:":[443],"appears":[445],"generally":[446],"tolerated":[448],"doses":[450],"tested":[451],"long":[457],"escalation":[463],"continues":[464],"define":[466],"MTD.":[470],"Antitumor":[471],"activity":[472],"various":[479],"cancers,":[480],"but":[482],"not":[483],"limited":[484],"those":[486],"genetic":[490],"alterations":[491],"(medullary":[494],"thyroid)":[495],"(papillary":[498],"renal).":[499]},"counts_by_year":[{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2016-06-24T00:00:00"}